Supernus Pharmaceuticals, Inc. (SUPN) Stock Score, Valuation & Financial Research
Supernus Pharmaceuticals, Inc. is in the Healthcare sector and Drug Manufacturers - Specialty & Generic industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 27/100.
Quick answer for SUPN
Supernus Pharmaceuticals, Inc. currently has a Wall Street Score of 27/100. The stored market price is $41.38. Its financial score is 37/100. Its valuation score is 0/100. These figures are a research snapshot, not a buy or sell recommendation.
What Supernus Pharmaceuticals, Inc. does
Supernus Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for central nervous system (CNS) disorders within the United States. Its portfolio of marketed products includes Trokendi XR, an extended-release topiramate formulation prescribed for both epilepsy management and migraine prevention. Another key product is Oxtellar XR, an extended-release oxcarbazepine designed for the standalone treatment of partial-onset epileptic seizures in patients aged 6 to 17 and adults. The company also offers Qelbree, a selective norepinephrine reuptake inhibitor approved for attention-deficit hyperactivity disorder (ADHD) in children and adolescents aged 6 to 17. For advanced Parkinson's Disease (PD) patients, APOKYN offers acute, intermittent relief during "off" episodes of hypomobility, and XADAGO serves as an adjunctive treatment with levodopa/carbidopa
SUPN financial snapshot
- Wall Street Score:
- 27/100
- Current price:
- $41.38
- Market capitalization:
- $2.40B
- Revenue:
- $776.8M
- Net income:
- $-29.0M
- Free cash flow:
- $46.0M
- Cash:
- $184.9M
- Total debt:
- $40.9M
- EPS:
- -0.68
- Financial score:
- 37/100
- Valuation score:
- 0/100
- Revenue score:
- 18/100
What stands out
- Reported year-over-year revenue growth is +0.1%.
- Free cash flow is $46.0M, showing positive cash generation.
- The balance sheet shows $184.9M of cash versus $40.9M of total debt, leaving more cash than debt.
What the numbers mean
Its current valuation score is 0/100, which Wall Street Score classifies as weak within the model's valuation framework.
The financial score is 37/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-07-24.
How to research SUPN
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.